Methylphenidate, a psycho-stimulant drug, also known by its 1948 trademarked name of Ritalin, could be useful in the treatment of excessive daytime sleepiness (EDS) for DM1 patients, according to a recent study conducted by The Department of Human Genetics at the Centre Hospitalier Universitaire de Quebec in Quebec City, Canada.
The Myotonic Dystrophy Foundation (MDF) is pleased to announce its most recent round of Fund-A-Fellow postdoctoral fellowship research grant awards. In January 2013, MDF awarded two $100,000 grants to postdoctoral Fellows working in universities and research facilities
A generic cardiovascular drug called mexiletine, initially developed to treat heart rhythm abnormalities, appears to hold some potential for treating muscle stiffness and other symptoms of non-dystrophic myotonias (NDMs),
Antisense oligonucleotides – short segments of genetic material designed to target specific areas of a gene
The new approach could have implications for many genetic diseases.